目的:观察芪莲肾炎丸治疗糖尿病肾病III期的临床疗效。方法选择60例糖尿病肾病III期患者,随机分为治疗组(30例)、对照组(30例)。两组均给予常规降压、降糖治疗,治疗组加用芪莲肾炎丸,分别于治疗前后观察两组患者的收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、尿微量白蛋白/肌酐比值(UACR)、血肌酐(Scr)、尿素氮(BUN)。结果:治疗组治疗12周后UACR较治疗前降低,与治疗前比较,UACR差异有统计学意义(P<0.01);对照组治疗前后UACR无明显变化,差异无统计学意义;空腹血糖(FPG)、收缩压(SBP)、舒张压(DBP)、血肌酐(Scr)、尿素氮(BUN)两组治疗前后均无明显变化(P>0.05)。结论:糖尿病肾病III期应用芪莲肾炎丸治疗,能降低尿微量白蛋白/肌酐比值(UACR),延缓糖尿病肾病早期进展。 Objective: To observe the clinical effect of Qilian nephritis pill in the treatment of stage Ⅲ diabetic nephropathy. Methods Sixty patients with stage III diabetic nephropathy were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were given routine antihypertensive and hypoglycemic treatment. The treatment group was treated with Qilian Nephritis Pills. The SBP, DBP, FPG and urine microalbuminuria were observed in both groups before and after treatment. Albumin / creatinine ratio (UACR), serum creatinine (Scr), blood urea nitrogen (BUN). Results: The UACR of the treatment group after 12 weeks of treatment was lower than that of before treatment, and the difference of UACR was statistically significant (P <0.01) before and after treatment. There was no significant difference in UACR before and after treatment in the control group (P> 0.05) SBP, DBP, Scr and BUN had no significant difference before and after treatment (P> 0.05). Conclusion: Treatment of diabetic nephropathy stage III with Qilian nephritis pill can reduce the urinary albumin / creatinine ratio (UACR) and delay the early progression of diabetic nephropathy.